Conference Details



Organizing Committee


Bayhelix China Healthcare Awards

2017 BayHelix China Healthcare Awards

For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. This year, BayHelix and BioCentury jointly hosted The "Bridge to Innovation" China Healthcare Summit (November 14-15, Shanghai), and expanded and presented the awards as the "China Healthcare Awards" in five categories:

R&D Achievement of the Year

Recognizing a scientific discovery in China with direct impact to drug and/or medtech R&D or a significant achievement in pharmaceutical and/or medtech development milestones.


Ascentage Pharma Group Corp. Ltd.

Six clinical development programs, including three innovative apoptosis-targeted drugs approved for clinical studies in the US in 2016-2017.

Deal of the Year

Recognizing a groundbreaking pharmaceutical and/or medtech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.


BeiGene Ltd./Celgene Corp.

Global strategic immuno-oncology collaboration between BeiGene and Celgene: Celgene to advance BeiGene's PD-1 inhibitor program BGB-A317 for solid tumor cancers, and BeiGene to assume responsibility of Celgene’s commercial operations and its oncology commercial portfolio in China to become a fully integrated biotech company.

Commercial Achievement of the Year

Recognizing a creative model that delivered superior value to patients/payers in China and commercial success.


WuXi Biologics Inc.

A powerful globally-leading end-to-end biologics discovery, development and manufacturing platform that is transforming the biologics industry by enabling anyone and any company to excel in biologics.

Company of the Year

Recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, medtech and/or healthcare industry.


Zai Lab Ltd.

Successful NASDAQ IPO after 3 years of company inception and a broad and sustainable pipeline.

Person of the Year

Recognizing an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or medtech R&D, deal transactions, and/or commercialization etc. in China.


Hao HONG, Ph.D., Chairman & CEO, Asymchem Laboratories Inc.

Built Asymchem in the last twenty years into one of the leading CDMO companies in the world and one of the global front-runners in green pharmaceutical manufacturing technologies, with proprietary green chemistry such as flow chemistry and biocatalysis.